VANCOUVER, July 6, 2017 /CNW/ - Isodiol International Inc.
(CSE: ISOL) (OTC: LAGBF) (Frankfurt: LB6A.F) (the "Company" or "Isodiol") a global cannabis innovator specializing in
the development of pharmaceutical and consumer products is pleased to announce it has received approval from the Brazilian Health
Regulatory Agency (ANVISA) for the approval of its pharmaceutical grade Cannabidiol (CBD) product, Isoderm™. This product will be
placed on the Special Category List for alternative therapies which will enable it to be prescribed by doctors and
neurologists.
Isodiol International CEO Marcos Agramont stated, "We had initially anticipated this process to
lead us into the third quarter, however receiving the first approval in a few months shows the quality and market demand for our
Isoderm™ product. We anticipate additional product and medical indication approvals to continue over the coming weeks and
months. We will strengthen our distribution relationships in the region and continue working towards receiving product
approvals in other jurisdictions. We will continue to be proactive and mitigate the regulatory risk in North America by increasing our footprint in countries that have approved medical CBD. By increasing
our global presence, we feel we will be in a position to influence the regulatory and legal framework of this movement into a
sustainable industry domestically in Canada and the US."
Additional information will be provided in the coming weeks around the progress of distribution partnerships.
About Isodiol International Inc.
Isodiol International, Inc. is the market leader in pharmaceutical grade cannabis compounds and the industry leader in
manufacturing and development of consumer products. Isodiol's nutraceutical division is the pioneer of many firsts for
Hemp-derived cannabidiol (CBD), including 99% pure crystalline isolate, micro-encapsulation, and nano technology for the highest
quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, seeking joint ventures
and acquisitions to expand its portfolio of brands and subsidiaries and will aggressively continue International expansion into
Latin America, Asia and Europe.
ON BEHALF OF THE BOARD
"Marcos Agramont"
CEO & Director
Join Us On Face Book:
https://www.facebook.com/isodiol/
Twitter: @isodiol
Forward-Looking Information: This news release contains "forward-looking information"
within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the
Company's business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations
reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be
correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are
subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those
contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from
those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required
by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or
forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward
looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no
reference to profitability based on sales reported. The statements in this news release are made as of the date of this
release.
The CSE has not reviewed, approved or disapproved the content of this press release.
SOURCE Isodiol International Inc.
View original content: http://www.newswire.ca/en/releases/archive/July2017/06/c5193.html